Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products designed to improve quality of care and address unmet medical needs. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose (lactulose) for Oral Solution, a prescription laxative, Vaprisol (conivaptan) Injection, for the treatment of hyponatremia and Omeclamox-Pak for the treatment of H. pylori and duodenal ulcer disease, and Ethyol (amifostine) for Injection, for the treatment of oncology patients. The Company also owns rights to ifetroban and are developing Hepatoren (ifetroban) Injection for the treatment of Hepatorenal Syndrome, Boxaban (ifetroban) Oral Capsule for the treatment of Aspirin-Exacerbated Respiratory Disease, VasculanTM (ifetroban) Oral Capsule for the treatment of systemic sclerosis, and Portaban, for the treatment of portal hypertension.
Company Growth (employees)
Cumberland Pharmaceuticals Office Locations
Cumberland Pharmaceuticals Financials and Metrics
Cumberland Pharmaceuticals Financials
Revenue (Q1, 2017) | 9.6 m |
Gross profit (Q1, 2017) | 8.3 m |
Gross profit margin (Q1, 2017), % | 86% |
Net income (Q1, 2017) | (1.3 m) |
EBIT (Q1, 2017) | (657.8 k) |
Market capitalization (20-Oct-2017) | 118.5 m |
Cash (31-Mar-2017) | 35 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 32 m | 36.9 m | 33.5 m | 33 m |
Revenue growth, % | 15% | (9%) | (1%) | |
Cost of goods sold | 5.4 m | 5.1 m | 5 m | 6 m |
Gross profit | 26.6 m | 31.8 m | 28.6 m | 27.1 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 9.8 m | 9.7 m | 8.7 m | 8.9 m | 7.9 m | 7.7 m | 7.4 m | 8.8 m | 9.6 m |
Cost of goods sold | 1.3 m | 1.3 m | 1.2 m | 1.2 m | 980.2 k | 1.2 m | 1.2 m | 2 m | 1.4 m |
Gross profit | 8.5 m | 8.4 m | 7.5 m | 7.7 m | 6.9 m | 6.5 m | 6.3 m | 6.8 m | 8.3 m |
Gross profit Margin, % | 87% | 86% | 87% | 86% | 88% | 84% | 84% | 78% | 86% |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 40.9 m | 39.9 m | 38.2 m | 34.5 m |
Inventories | 5.7 m | 5.6 m | 4.3 m | 5.4 m |
Current Assets | 68.7 m | 70.8 m | 67.1 m | 65.5 m |
PP&E | 880.6 k | 651 k | 536.5 k | 464.5 k |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 39.1 m | 39.6 m | 39 m | 38.9 m | 38.3 m | 36.4 m | 35.8 m | 35.5 m | 35 m |
Inventories | 7 m | 6.1 m | 4.6 m | 4.8 m | 4.2 m | 4.1 m | 4.9 m | 5 m | 5.6 m |
Current Assets | 70.6 m | 70.1 m | 67.5 m | 68.2 m | 67.7 m | 64.9 m | 64 m | 67 m | 63.5 m |
PP&E | 726.9 k | 731.1 k | 685.2 k | 568.8 k | 541.8 k | 558.2 k | 505.7 k | 482.6 k | 538.4 k |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (2.2 m) | 2.4 m | 671.1 k | (1 m) |
Depreciation and Amortization | 1.3 m | 2 m | 2.2 m | 2.4 m |
Accounts Receivable | 1.5 m | (974.3 k) | (572.4 k) | (1.3 m) |
Inventories | 495.5 k | 1.5 m | 1.3 m | (1.1 m) |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | 709.5 k | 729.2 k | 26.5 k | 394.3 k | 121.7 k | (268.6 k) | (60.9 k) | 95.5 k | (1.3 m) |
Inventories | 7 m | 6.1 m | 4.6 m | 4.8 m | 4.2 m | 4.1 m | 4.9 m | 5 m | |
Accounts Payable | 4.2 m | 3.2 m | 3.4 m | 4.1 m | 4.1 m | 4.1 m | 3.7 m | 6.7 m | 7.3 m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 117.5 k |
Financial Leverage | 1.3 x |
